Technology

According to industry sources, the $123 B. WW cancer drug market is the biggest and fastest growing segment of the pharma industry. This growth is driven by the approach of Precision Oncology, the molecular profiling of tumors to identify individualized targeted therapy.  This treatment is based on a patient’s individual biological cancer blue print: effective but also extremely expensive. 

This expensive and individualized approach requires better companion diagnostics to justify the high cost of the drug:  to identify the appropriate targets for therapy, to assess whether the therapy is reaching the target, and to assess how the target is responding to therapy.